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Abstract  
The interplay between BDNF signaling and the serotonergic system remains incompletely understood. Using 
a highly sensitive enzyme-linked immunosorbent assay, we studied BDNF concentrations in hippocampus 
and cortex of two mouse models of altered serotonin signaling: tryptophan hydroxylase (Tph)2-deficient 
(Tph2-/-) mice lacking brain serotonin and serotonin transporter (SERT) deficient (SERT-/-) mice lacking 
serotonin re-uptake. Surprisingly, hippocampal BDNF was significantly elevated in Tph2-/- mice, whereas no 
significant changes were observed in SERT-/- mice. Furthermore, BDNF levels were increased in the 
prefrontal cortex of Tph2-/- but not of SERT-/- mice. Our results emphasize the interaction between serotonin 
signaling and BDNF. Complete lack of brain serotonin induces BDNF expression.  
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Introduction 
 
5-hydroxytryptamine (serotonin) is synthesized in the brain stem raphe nuclei by the neuron-specific enzyme 
tryptophan hydroxylase (TPH) 2 [1]. Upon release, extracellular concentrations of serotonin are regulated by 
plasmalemmal re-uptake into the pre-synaptic neuron/boutons via SERT (5-HTT, SLC6A4), which is widely 
expressed in the brain and constitutes a chief target for antidepressant psychopharmacotherapy [2, 3]. BDNF 
is the most abundant neurotrophin in the adult hippocampus and cortex of rodents [4]. Apart from local 
biosynthesis, BDNF protein is also supplied by anterograde neuronal trafficking [5]. Both central serotonin 
and BDNF signaling are crucially involved in shaping important aspects of brain plasticity such as synaptic 
plasticity and the generation and survival of new neurons in the hippocampus [6, 7]. Importantly, chronic 
treatment with a selective serotonin re-uptake inhibitor (SSRI) has been shown to increase the expression of 
cAMP response element binding protein (CREB) and of CREB target gene BDNF in the hippocampus [8-10]. 
Conversely, serotonin neurotransmission is under the influence of BDNF [11, 12].  
 
Mouse models genetically modified for altered serotonin signaling open an exciting new window on brain 
plasticity and may shed new light on the neurobiology of depression and mechanisms of antidepressant 
actions [13]. Here, we measured BDNF protein levels in Tph2-/- mice that lack brain serotonin (and show 
certain features of depression-like behaviors such as impaired maternal care and increased immobility in the 
Porsolt forced swim test; reviewed in [14]), and SERT-/- mice, which exhibit increased extracellular serotonin 
levels [15, 16] despite an overall reduction (60 to 80%) in serotonin tissue concentrations [17]. 
 
In the adult hippocampus, chronic SSRI treatment increases precursor cell proliferation and neurogenesis 
[18]. It might therefore be speculated that impaired serotonergic signaling is also accompanied by reduced 
neurogenesis. However, we and others have recently shown that in adult mice modified for no (Tph2-/-, 
VMAT2SERT-Cre) or reduced brain serotonin (Tph2KI, Pet1-/-) baseline levels of cell proliferation in the dentate 
gyrus are unexpectedly normal (reviewed in [19]). We speculate that sustained cell proliferation under 
conditions of serotonin deficiency most probably is the result of developmental compensation by other factors 
in the niche, e.g., BDNF.  
 
 
Methods  
 
Animals 
The generation of Tph2-/- and SERT-/- mice has been described in detail elsewhere [15, 20]. Both Tph2-/- and 
SERT-/- mice have been established on a pure C57BL/6 genetic background [21]. Animals were 10 to 12 
weeks old at the time of sacrifice. Age and background-matched wild type (WT) mice were used in all 
experiments. All mice were kept in the same room under a controlled environment (12/12 h light-dark cycle, 
free access to food and water). All procedures were approved by the respective official committees (LaGeSo) 
and carried out in accordance with the Animal Welfare Act and the European Communities Council Directive 
of November 24, 1986 (86/609/EEC).  
 
Tissue preparation and enzyme-linked immunosorbent assay (ELISA) 
After sacrifice, brains were quickly removed. Prefrontal cortex and hippocampus were dissected, snap-frozen 
in liquid nitrogen, and then stored at -80 °C until further use. Endogenous levels of BDNF were measured in 
the rethawed homogenates using commercial ELISA kits in principle according to the manufacturer's 
instructions (Promega) but adapted to a highly sensitive fluorometric technique as described in detail 
elsewhere [22]. BDNF content was expressed as equivalents of recombinant human BDNF. The detection 
limit of the assay was 1 pg/ml. Determinations of recovery and specific and unspecific neurotrophin binding 
(the latter against mouse IgG1 obtained from MOPC 21) involved triplicate fluorescence determinations for 
each tissue sample. Using this improved fluorometric ELISA, it was feasible to quantify BDNF in brain tissue 
with a minimal wet weight of approximately 5 pg [23, 24]. BDNF levels were expressed as picograms per 
milligram of tissue (wet weight). 
 
Statistics 
Statistical differences between group means were evaluated by ANOVA followed by Tukey’s post hoc test 
when appropriate (GraphPad PRISM 5.01 software). For individual comparisons, a Student’s t test was used. 
All values are expressed as mean ± SEM. P values of <0.05 were considered statistically significant.  
 
 
Results 
 
The results of ELISA measurements are summarized in Figure 1. BDNF protein concentrations in 
hippocampus were generally higher than in cortex. A genotype effect was observed for Tph2-/- mice (ANOVA 
F(5,50) = 15.23, p < 0.0001) with significantly increased BDNF levels in the hippocampus of female and 
male Tph2-/- mice relative to WT (Student’s t test p = 0.0442, and p = 0.0280, respectively; Figure 1A). 
Furthermore, cortical BDNF concentrations were significantly increased in Tph2-/- mice compared with WT 
(Student’s t test p = 0.0165). We did not detect significant effects of SERT-/- genotype on BDNF expression 
(Figure 1B).  
 
 
Discussion 
 
In this study, we assessed BDNF levels in the adult hippocampus and cortex of two mouse models with 
altered brain serotonin signaling. Using an improved fluorometric ELISA, BDNF protein content in brain 
tissue was quantitatively evaluated. As described in the methods section, the ELISA procedure employed here 
is characterized by a very high sensitivity and is far superior to alternative methods described for the 
quantification of the BDNF protein such as immunohistochemistry or immunoblotting [23, 24]. We would 
also like to point out that earlier studies in experimental mice yielded very similar absolute BDNF 
concentrations to the values reported here. Moreover, a generally similar pattern of sex-specific differences in 
BDNF levels has been described [25]. Furthermore, it should be noted that the concentration of the bioactive 
BDNF protein in a given brain structure cannot simply be extrapolated from BDNF mRNA expression in that 
structure. Indeed, discrepancies between BDNF mRNA and protein have been described in the literature [26]. 
These discrepancies may relate to protein trafficking and changes in BDNF mRNA stability [27, 28].  
 
The major finding of our study is that BDNF concentrations are significantly increased in the brains of Tph2-/- 
mice in all regions investigated. We argue that increased BNDF levels in these animals may reflect a 
compensatory mechanism of the brain in the absence of serotonin. Our study confirms and extends to the 
protein level the results by Migliarini and co-workers [29]. They reported increased BDNF gene transcription 
in the hippocampus of a knock-in mouse line in which the Tph2 gene is replaced by enhanced green 
fluorescent protein (eGFP). However, in that study, BDNF mRNA expression changes were rather subtle and 
did not yield statistically significant differences in the cortex [29]. Our results are also directly relevant to the 
situation in the human brain, where a loss-of-function mutation in the Tph2 gene has been described resulting 
in an approximately 80% decrease in serotonin production [30]. We speculate that similar changes may also 
accompany the severe serotonergic damage that has been described with 3,4-
methylenedioxymethamphetamine (MDMA) use [31].  
 
The literature on SERT and BDNF signaling yields a somewhat complicated picture. Inhibition of SERT 
function that leads to increased serotonin levels in the synaptic cleft is thought to be the main therapeutic 
target of SSRIs. In turn, chronic administration of sertraline increases hippocampal BDNF mRNA levels in 
rats [9]. Similarly, SSRI-induced increases in serum BDNF levels have been detected in depressed patients 
[32]. Furthermore, SERT heterozygous null mice subjected to poor maternal care show elevated hippocampal 
BDNF mRNA levels relative to wild type controls undergoing identical experimental procedures [33]. Our 
data of slightly increased BDNF protein in the hippocampus of SERT-deficient mice seems to fit with these 
findings. Conceptually, mild increases in BDNF protein content in SERT-/- mice with reduced serotonin 
concentrations in brain tissue also fit well with more robust BDNF increases in Tph2-/- mice that lack brain 
serotonin completely. However, our results differ somewhat from other studies that found reduced BDNF 
signaling in the ventral hippocampus and prefrontal cortex of SERT deficient rats [34, 35]. Finally, another 
study of BDNF conducted in SERT+/+, SERT+/- and SERT-/- mice did not yield any significant differences in 
BDNF protein levels between genotypes in hippocampus, frontal cortex, and brain stem [36]. In line with this 
report, we also did not detect altered BDNF levels in the prefrontal cortex of the SERT-/- mouse strain used in 
our study. Regarding the hippocampus, it also has to be noted that a recent study in SERT mutant rats adds a 
new level of complexity by suggesting that BDNF expression may differ in different hippocampal subfields 
[34].  
 
Taken together, our study adds to a growing body of evidence showing that the serotonergic system and the 
BDNF system interact. Strikingly, loss of central serotonin promotes BDNF protein expression.  
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Legends 
 
Figure 1.  
BDNF protein levels in the hippocampus and prefrontal cortex of Tph2-/- and SERT-/- mice. (A) BDNF protein 
levels were increased in female (n = 8) and male (n = 7) hippocampi, and prefrontal cortex of female Tph2-/- 
mice in comparison to WT. (B) No statistically significant changes in BDNF concentrations were measured in 
the adult hippocampus and prefrontal cortex of female SERT-/- mice (n = 6). Notably, BDNF levels were 
generally lower in the prefrontal cortex than in the hippocampus. *P < 0.05 indicates statistical significance 
between genotypes, and #p < 0.05, ##p < 0.01, ###p < 0.001 to hippocampus of female mice of the same 
genotype, Student’s t test; data are presented as mean ± SEM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
